Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118

The Journal of Infectious Diseases
Laura RomanoMaurizio Zazzi

Abstract

Two large, independent human immunodeficiency virus type 1 resistance databases containing >7700 reverse-transcriptase (RT) sequences were used to analyze the epidemiology of amino acid substitutions at codons 44 and 118, which confer moderate lamivudine resistance in the presence of zidovudine resistance. As expected, E44A/D and V118I mutations were strongly associated with M41L, D67N, L210W, and T215Y but also with other mutations, including K43E/N/Q, T69D, V75M, H208Y, R211K, and K219R. Both E44D and V118I were more frequently associated with stavudine and didanosine than with zidovudine and lamivudine treatment. However, selection of E44A/D and V118I was also detected in association with a switch to other nucleoside RT inhibitors, including zalcitabine and abacavir. Site-directed mutagenesis confirmed that 44D and 118I can decrease phenotypic susceptibility not only to lamivudine but also to most other nucleoside analogues, particularly stavudine and abacavir. Thus, substitutions at RT codons 44 and 118 have broad implications in nucleoside RT inhibitor resistance in the setting of several nucleoside-associated mutations.

Citations

Mar 12, 2004·International Journal of Antimicrobial Agents·M C ReUNKNOWN HIV-1 Emilia Romagna Infectious Disease Study Group
Sep 21, 2010·Nature Structural & Molecular Biology·Xiongying TuEddy Arnold
Oct 25, 2008·Nucleic Acids Research·Na LiAndrew D Ellington
Dec 18, 2012·Journal of Clinical Microbiology·Moussa ThiamCoumba Toure-Kane
Oct 22, 2002·Expert Opinion on Biological Therapy·Bluma G BrennerMark A Wainberg
Jul 19, 2005·Virus Research·D ParaskevisUNKNOWN Hellenic Multi-centre study on HIV-resistance
Dec 8, 2004·Current Opinion in Structural Biology·Stefan G SarafianosEddy Arnold
Nov 16, 2005·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Ruengpung SutthentSombat Tanprasertsuk
Nov 22, 2008·Journal of Molecular Biology·Stefan G SarafianosEddy Arnold
Jan 7, 2003·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Chris BirchSean Emery
Aug 2, 2003·AIDS·Françoise Brun-VézinetUNKNOWN Narval (ANRS 088) Study group
Mar 16, 2007·The Journal of Antimicrobial Chemotherapy·G NebbiaUNKNOWN UK Collaborative HIV Cohort (CHIC) Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.